positive COVID–19 test result may be submitted by 3pm the business day prior to the hearing. Further information about participation in the hearing will be posted on the Commission's website at *https://www.usitc.gov/calendarpad/calendar.html.*

A nonparty who has testimony that may aid the Commission's deliberations may request permission to present a short statement at the hearing. All parties and nonparties desiring to appear at the hearing and make oral presentations should attend a prehearing conference, if deemed necessary, to be held at 9:30 a.m. on Tuesday, April 15, 2025. Parties shall file and serve written testimony and presentation slides in connection with their presentation at the hearing by no later than noon on April 14, 2025. Oral testimony and written materials to be submitted at the public hearing are governed by sections 201.6(b)(2), 201.13(f), and 207.24 of the Commission's rules. Parties must submit any request to present a portion of their hearing testimony *in camera* no later than 7 business days prior to the date of the hearing.

Written submissions—Each party who is an interested party shall submit a prehearing brief to the Commission. Prehearing briefs must conform with the provisions of § 207.23 of the Commission's rules; the deadline for filing is April 10, 2025. Parties shall also file written testimony in connection with their presentation at the hearing, and posthearing briefs, which must conform with the provisions of § 207.25 of the Commission's rules. The deadline for filing posthearing briefs is April 24, 2025. In addition, any person who has not entered an appearance as a party to the investigations may submit a written statement of information pertinent to the subject of the investigations, including statements of support or opposition to the petition, on or before April 24, 2025. On May 12, 2025, the Commission will make available to parties all information on which they have not had an opportunity to comment. Parties may submit final comments on this information on or before May 14, 2025, but such final comments must not contain new factual information and must otherwise comply with § 207.30 of the Commission's rules. All written submissions must conform with the provisions of § 201.8 of the Commission's rules; any submissions that contain BPI must also conform with the requirements of §§ 201.6, 207.3, and 207.7 of the Commission's rules. The Commission's *Handbook on Filing Procedures,* available on the Commission's website at *https://www.usitc.gov/documents/handbook_on_filing_procedures.pdf,* elaborates upon the Commission's procedures with respect to filings.

Additional written submissions to the Commission, including requests pursuant to § 201.12 of the Commission's rules, shall not be accepted unless good cause is shown for accepting such submissions, or unless the submission is pursuant to a specific request by a Commissioner or Commission staff.

In accordance with §§ 201.16(c) and 207.3 of the Commission's rules, each document filed by a party to the investigations must be served on all other parties to the investigations (as identified by either the public or BPI service list), and a certificate of service must be timely filed. The Secretary will not accept a document for filing without a certificate of service.

Authority: These investigations are being conducted under authority of title VII of the Tariff Act of 1930; this notice is published pursuant to § 207.21 of the Commission's rules.

By order of the Commission.

Issued: December 16, 2024.

Lisa Barton,

Secretary to the Commission.

[FR Doc. 2024–30379 Filed 12–19–24; 8:45 am]

BILLING CODE 7020–02–P

DEPARTMENT OF JUSTICE

Antitrust Division

Notice Pursuant to the National Cooperative Research and Production Act of 1993—1EdTech Consortium, Inc.

Notice is hereby given that, on July 16, 2024, pursuant to section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* (''the Act''), 1EdTech Consortium, Inc. (''1EdTech Consortium'') has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act's provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances.

Specifically, Alabama Institute for Deaf and Blind, East Talladega, AL; Education Assessment System, Arlington, VA; University of Georgia, Athens, GA; School Harbor, Phoenix, AZ; Ivy Tech Community College, Indianapolis, IN; MyEducator LLC, Orem, UT; Mountain Brook Schools, Mountain Brook, AL; Uinta County School District #1, Evanston, WY; St. Charles CUSD 303, St. Charles, IL; Swedish National Agency for Education (Statens skolverk), Stockholm, SWEDEN; Massachusetts Institute of Technology, Cambridge, MA; and Vestavia Hills City Schools, Vestavia Hills, AL, have been added as parties to this venture.

Also, Washington State Community and Technical Colleges System, Olympia, WA; Pearl, Richmond, VA; New Hanover County Schools, Wilmington, NC; and Edge Factor Inc., Ontario, CANADA, have withdrawn as parties to this venture.

No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and 1EdTech Consortium intends to file additional written notifications disclosing all changes in membership.

On April 7, 2000, 1EdTech Consortium filed its original notification pursuant to section 6(a) of the Act. The Department of Justice published a notice in the **Federal Register** pursuant to section 6(b) of the Act on September 13, 2000 (65 FR 55283).

The last notification was filed with the Department on April 29, 2024. A notice was published in the **Federal Register** pursuant to section 6(b) of the Act on June 21, 2024 (89 FR 52089).

Suzanne Morris,

Deputy Director Civil Enforcement Operations, Antitrust Division.

[FR Doc. 2024–30406 Filed 12–19–24; 8:45 am]

BILLING CODE P

DEPARTMENT OF JUSTICE

Antitrust Division

Notice Pursuant to the National Cooperative Research and Production Act of 1993—Rapid Response Partnership Vehicle

Notice is hereby given that, on October 3, 2024, pursuant to section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* (''the Act''), Rapid Response Partnership Vehicle (''RRPV'') has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act's provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances.

Specifically, Biointelect Pty, Ltd., Sydney, AUSTRALIA; SPI Pharma, Inc.,

Wilmington, DE; Serimmune, Goleta, CA; UNITED KINGDOM HEALTH SECURITY AGENCY (UKHSA), Salisbury, UNITED KINGDOM; University of Connecticut, Farmington, CT; VGXI, Inc., Conroe, TX; ABSS Solutions, Inc., Upper Marlboro, MD; BiosYnth SRL, Milan, ITALY; Idevax, Wijnegem, BELGIUM; IntegerBio, Inc., Gaithersburg, MD; Phoreus Biotechnology, Inc., Olathe, KS; PrecNA, LLC, North Potomac, MD; Sepragen Corp., Union City, CA; Trellis Bioscience, Inc., Redwood City, CA; AB Validation, Inc., Quebec, CANADA; AuraVax Therapeutics, Inc., Houston, TX; CuriRx, Inc., Wilmington, MA; IMA Evaluations, LLC, dba IMA Clinical Research, Tarrytown, NY; MustardSeed PMO, West Chester, PA; Symbiosis.io, LLC, Smyrna, GA; Tornado Therapeutics, Boston, MA; Amneal Pharmaceuticals of New York, LLC, Brookhaven, NY; Blue Spark Technologies, Inc., Westlake, OH; Inhalon Biopharma, Inc., Morrisville, NC; Intelligene, Inc., Taipei, TAIWAN; Rocket Science Health US Corp., Seattle, WA; Rutgers, The State University of New Jersey, Piscataway, NJ; The Administrators of the Tulane Educational Fund, New Orleans, LA; Verisim Life, Inc., San Francisco, CA; Arcturus Therapeutics Holdings, Inc., San Diego, CA; Blu Zone Bioscience & Supply Chain Solutions, LLC, Frederick, MD; Elligo Health Research, Inc., Austin, TX; Guide Biomedical Solutions, LLC, Media, PA; Integral Molecular, Philadelphia, PA; Komo Biosciences, Inc., Newton, MA; P95, BV, Leuven, BELGIUM; Southwest Research Institute, San Antonio, TX; Statistics & Data Corp., Tempe, AZ; Stoic Bio, Inc., San Diego, CA; Valaria Technical Consultants, LLC, Westminster, MD; Vaxine Pty, Ltd., Marion, AUSTRALIA; Zeteo Biomedical, LLC, Austin, TX; Concept to Market, LLC, Monrovia, MD; DSBio Consulting, LLC, Annapolis, MD; Deimos Biosciences, San Francisco, CA; GMED North America, Inc., Rockville, MD; InvisiShield Technologies, Ltd., Emeryville, CA; MigVax, Ltd., Kiryat Shmona, ISRAEL; Polaris Alpha Advanced Systems, Inc., Fredericksburg, VA; Pop Test Oncology, LLC, Cliffside Park, NJ; Sapphiros, Boston, MA; Articulate Labs, Inc., Dallas, TX; Empatica, Inc., Cambridge, MA; LifeMine Therapeutics, Inc., Cambridge, MA; Luminous Therapeutics Corp., Columbia, MD; Nabla Bio, Inc., Cambridge, MA; Qoolabs, Inc., Carlsbad, CA; Rapid Novor, Inc., Kitchener, CANADA; Scorpius BioManufacturing, San Antonio, TX; Sunflower Therapeutics PBC, Medford, MA; GreenRoads Diagnostics, Inc., San Diego, CA; Logical Images, dba ''VisualDx'', Rochester, NY; Mirai Biosciences, Cambridge, MA; The Scripps Research Institute, La Jolla, CA; AmplifyBio, LLC, West Jefferson, OH; Andelyn Biosciences, Inc., Columbus, OH; Binary Pharmaceuticals, LLC, Hot Springs, AR; BioCina PTY, Ltd., West Torrens, AUSTRALIA; Cypress Biologics, LLC, Portland, OR; Fermeate, Inc., San Francisco, CA; HMH Hospitals Corp, dba CDI, Nutley, NJ; Meso Scale Diagnostics, LLC, Rockville, MD; Systems & Technology Research, LLC, Woburn, MA; Telesis Bio, San Diego, CA; Thermo Fisher, South San Francisco, CA; University of Massachusetts Lowell, Lowell, MA; ViQi, Inc., Santa Barbara, CA; DemeTech Corp., Miami, FL; INFEX Therapeutics, Alderley Edge, UNITED KINGDOM; Mercury Bio, Inc., Santa Fe, NM; Phageolytix, Inc., Jacksonville, FL; Phenom Pharmaceuticals, LLC, Miami Beach, FL; RIBOPRO BV, Oss, NETHERLANDS; RNhale GmbH, Munich, GERMANY; The University of Chicago Medicine, Chicago, IL; Bioblue CMC/Manufacturing Consulting, LLC, San Diego, CA; Oligo Foundry, Inc., San Diego, CA; PNUVAX, Inc., Wilmington, DE; Prosoft Software, Inc., dba Prosoft Clinical, Chesterbrook, PA; Simon Williams Pharma Consulting (SWPC), LLC, Gibbsboro, NJ; Dillico, Meylan, FRANCE; INFINIFLUIDICS, Philadelphia, PA; Primrose Bio, Inc., San Diego, CA; SIMETRI, Inc., Winter Park, FL; The Trustees of the University of Pennsylvania, Philadelphia, PA; and WCG, Princeton, NJ, have been added as parties to this venture.

No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and RRPV intends to file additional written notifications disclosing all changes in membership.

On January 5, 2024, RRPV filed its original notification pursuant to section 6(a) of the Act. The Department of Justice published a notice in the **Federal Register** pursuant to section 6(b) of the Act on April 16, 2024 (89 FR 26928).

The last notification was filed with the Department on July 11, 2024. The Department of Justice published a notice in the **Federal Register** pursuant to section 6(b) of the Act on October 11, 2024 (89 FR 82631).

Suzanne Morris,

Deputy Director Civil Enforcement Operations, Antitrust Division.

[FR Doc. 2024–30403 Filed 12–19–24; 8:45 am]

BILLING CODE P

DEPARTMENT OF JUSTICE

Antitrust Division

Notice Pursuant to the National Cooperative Research and Production Act of 1993—UHD Alliance

Notice is hereby given that, on October 8, 2024, pursuant to section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* (''the Act''), UHD Alliance, Inc. (''UHD Alliance'') filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act's provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, TTE Corporation, Shenzhen, PEOPLE'S REPUBLIC OF CHINA has been added as a party to this venture.

No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and UHD Alliance intends to file additional written notifications disclosing all changes in membership.

On June 17, 2015, UHD Alliance filed its original notification pursuant to section 6(a) of the Act. The Department of Justice published a notice in the **Federal Register** pursuant to section 6(b) of the Act on July 17, 2015 (80 FR 42537).

The last notification was filed with the Department on July 8, 2024. A notice was published in the **Federal Register** pursuant to section 6(b) of the Act on September 26, 2024 (89 FR 78904).

Suzanne Morris,

Deputy Director Civil Enforcement Operations, Antitrust Division.

[FR Doc. 2024–30412 Filed 12–19–24; 8:45 am]

BILLING CODE P

DEPARTMENT OF JUSTICE

Antitrust Division

Notice Pursuant to the National Cooperative Research and Production Act of 1993—Subcutaneous Drug Development & Delivery Consortium, Inc.

Notice is hereby given that, on October 4, 2024, pursuant to section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* (''the Act''), Subcutaneous Drug Development & Delivery